Elevated mRNA expression levels of PLCβ1, PLCβ2, and PLCβ3 were associated with poor overall survival in every NSCLC patient in the study and were significantly associated with poor prognosis in adenocarcinoma cases. Here, PLCB1 is linked to non-small cell lung carcinoma.